Clinical Trial

Comprehensive Demographics and Clinical Profile of NSCLC Patients

Study acronym: CA209-1529
Not Yet Recruiting
View on ClinicalTrials.gov →
Record status
This record was last updated January 15, 2025 (before its estimated March 1, 2025 completion). Its status may not reflect the trial's current state.
Summary
Advances in the treatment of non-small cell lung cancer in the last decade have been significant. Currently, there are several first-line therapeutic options. The molecular biology of the disease, biomarkers and the patient's clinical characteristics can assist in decision making. The study in question aims to retrospectively evaluate the patterns of choice in the first line treatment of metastatic non-small cell lung cancer without driver mutations, from 2019 to 2022 in 7 centers in Brazil.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2024-12-05.
Trial Details
NCT Number NCT06725537
Lead Sponsor D'Or Institute for Research and Education
Collaborators: Bristol-Myers Squibb
Conditions Lung Cancer Non Small Cell
Enrollment 500 participants
Start Date 2025-01-20
Primary Completion 2025-03-01 (estimated)
Study Completion 2025-08-01 (estimated)
Updated on ClinicalTrials.gov 2025-01-15